M-M-R II Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This M-M-R II market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to expanded health insurance coverage, increased focus on preventative healthcare, heightened public awareness about vaccine safety, growing demand for convenient vaccination services, and increased need for travel vaccines.

Growth during the forecast period can be linked to greater awareness of waning immunity, efforts to address vaccine hesitancy, the use of telemedicine to promote vaccine awareness, the role of community immunization advocates, and the expansion of private-sector vaccine distribution networks. Key trends expected in this period include the creation of combination vaccines, advancements in pharmaceutical innovation, the development of thermostable vaccine formulations, the adoption of digital immunization records, and improvements in cold chain technology.

The growing number of cases of measles, mumps, and rubella is expected to drive the expansion of the M-M-R II market. These diseases are highly contagious and can lead to severe health complications, including fever, rash, swelling, and in some cases, neurological damage or congenital disabilities if rubella is contracted during pregnancy. The increase in these diseases can be attributed to factors such as lower vaccination rates, gaps in immunization coverage, and vaccine hesitancy in certain groups. The M-M-R II vaccine protects against measles, mumps, and rubella by stimulating the immune system to produce antibodies that prevent infection and serious health issues. For example, in May 2024, the UK Health Security Agency reported 51 confirmed cases of mumps in England between January and March 2023, up from 32 in the previous quarter and 10 in the July to September 2022 period. During the same timeframe, 31 cases of measles were reported, compared to just 7 cases in the previous quarter. These rising incidences of the diseases are driving the demand for the M-M-R II vaccine.

The growth of the M-M-R II market is also being fueled by the increasing success rates of vaccination programs. These programs, which are organized by governments or health organizations to administer vaccines and prevent the spread of infectious diseases, have seen high success due to factors such as public awareness, effective distribution systems, government support, and the availability of safe, effective vaccines. Vaccination programs play a vital role in promoting the M-M-R II vaccine, which reduces the incidence of measles, mumps, and rubella, thus improving public health. For instance, according to the UK Health Security Agency, during the 2022-2023 school-aged vaccination program, 3,502,566 children between Reception and Year 9 were vaccinated, slightly lower than the 3,615,536 children vaccinated in the same age group in the 2021-2022 period. This increasing success of vaccination programs contributes to the growth of the M-M-R II market.

A key trend in the M-M-R II market is the development of innovative therapies such as live attenuated vaccines, which aim to improve immunization effectiveness and expand protection against measles, mumps, and rubella. A live attenuated vaccine contains a weakened version of the pathogen that can still stimulate an immune response without causing the disease. In March 2023, Merck & Co. Inc. received approval from the U.S. Food and Drug Administration for the intramuscular administration of the M-M-R II vaccine, which is used to prevent measles, mumps, and rubella in individuals aged 12 months and older. The vaccine is typically administered intramuscularly or subcutaneously, with the first dose recommended at 12 to 15 months and a second dose at 4 to 6 years.

The key player in the M-M-R II market is Merck & Co. Inc.

North America was the largest region in the M-M-R II market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in M-M-R II report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the M-M-R II market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

M-M-R II is a combination vaccine designed to provide protection against three viral infections, measles, mumps, and rubella. It contains live, attenuated (weakened) versions of these viruses, enabling the immune system to recognize and combat them without causing illness. The vaccine is generally administered in a two-dose series, with the first dose given between 12 and 15 months of age and the second between 4 and 6 years, as part of standard childhood immunization schedules.

M-M-R II is primarily indicated for the prevention of measles, mumps, and rubella. Measles is an extremely contagious viral illness marked by fever, cough, a runny nose, and a characteristic red, blotchy rash. The vaccine is available in live attenuated formulations and pre-filled syringes, and it is distributed through hospitals, pediatric clinics, public health organizations, and retail pharmacies. Its primary users include patients across various age groups, such as infants, children, and adults.

The M-M-R II market research report is one of a series of new reports that provides M-M-R II market statistics, including M-M-R II industry global market size, regional shares, competitors with a M-M-R II market share, detailed M-M-R II market segments, market trends and opportunities, and any further data you may need to thrive in the M-M-R II industry. This M-M-R II market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The M-M-R II market consists of sales of single antigen vaccines, proquad vaccine, priorix vaccine, and ruvax vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.